[Pharmacotherapeutic assessment of antiosteoporotic properties of alpha-calcidol in chronic obstructive pulmonary disease].
To evaluate antiresorptive properties of alphacalcidol in the treatment of osteopenic syndrome in patients with chronic obstructive pulmonary disease (COPD). A total of 94 COPD patients with low densitometric indices were studied for bone densitometric parameters, calcium-phosphorus metabolism, markers of bone tissue metabolism (osteocalcine-OC, tartrate-resistent acid phosphatase--TRAP, beta CrossLaps - BCL), cytokine profile in the course of 6-month continuous therapy with alpha-calcidol (alpha-D3-TEVA) in a dose 0.75-1 mcg/day. Six-month treatment with alpha-calcidol relieved pain, increased bone densitometric parameters, normalized calcium-phosphorus metabolism. While 3-month therapy induced positive dynamics in markers of bone metabolism (OC level increased, concentrations of BCL, TRAP reduced), 6-month therapy resulted in these parameters normalization close to the level of healthy persons. Proinflammatory cytokines (IL-1beta, IL-6 TNF-alpha) in COPD lowered significantly. Alpha-calcidol have analgetic, antiresorptive and immunomodulating effects which make this drug effective in prevention and pathogenetic therapy of osteopenic syndrome in COPD.